XM does not provide services to residents of the United States of America.
B
B

BayerAG

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P

Companies ask US judiciary group to force lawsuit funding disclosures

Companies ask US judiciary group to force lawsuit funding disclosures By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits. Companies including Amazon.com, Google, Cisco, Meta, Comcast, Exxon, Zurich, Eli Lilly, Bayer, Ford, Pfizer and Novartis submitted the letter on Wednesday to the federal cou
A
B
C
G
N
P

Bayer sees Intacta2 Xtend GMO seed covering 30% of Brazil's soybeans

Bayer sees Intacta2 Xtend GMO seed covering 30% of Brazil's soybeans SAO PAULO, Oct 3 (Reuters) - Germany's Bayer BAYGn.DE forecasts that some 30% of Brazil's soybean area will be sowed with its genetically modified biotech seed Intacta2 Xtend in the 2024/25 season, doubling the share from the previous crop, a top executive said this week. The exact share Intacta2 Xtend will reach should be clear only in some two or three weeks after expected rains allow a broad planting in Brazil's soy fields,
B

India's Shivalik Rasayan climbs on US FDA approval for facility

BUZZ-India's Shivalik Rasayan climbs on US FDA approval for facility ** Shares of Shivalik Rasayan SIVA.NS rise 13.1% to 639.9 rupees ** Agrochemicals and active pharma ingredients (API)-maker received U.S. FDA approval for its API facility in India's Gujarat state ** Stock eyes best day since July 3 ** SIVA down ~14% YTD; agrochemical rivals UPL U
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.